Trial Profile
A phase I study of TAS-102 and irinotecan in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 14 Oct 2015 New source identified and integrated, (JapicCTI132099).
- 14 Oct 2015 New trial record